The phase 3 LITESPARK-022 trial reported that combining belzutifan, a HIF-2α inhibitor, with pembrolizumab extends disease-free survival in patients with high‑risk clear cell renal cell carcinoma after surgery. Trial sponsors disclosed the disease‑free survival benefit at a recent data release, positioning the regimen as a new adjuvant option under evaluation. Belzutifan—already approved in other settings—and pembrolizumab’s established checkpoint activity make the result clinically notable. Sponsors and investigators will need to disclose full survival curves, safety data, and regulatory plans to determine whether the combination will pursue label expansion or accelerated review.